Borghaei H - Search Results

1

Targeted therapies in solid tumors: monoclonal antibodies and small molecules.

Weiner LM, Borghaei H. Weiner LM, et al. Among authors: borghaei h. Hum Antibodies. 2006;15(3):103-11. Hum Antibodies. 2006. PMID: 17065741

2

Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.

Borghaei H, Wallace SG, Schilder RJ. Borghaei H, et al. Clin Lymphoma. 2004 Oct;5 Suppl 1:S16-21. doi: 10.3816/clm.2004.s.004. Clin Lymphoma. 2004. PMID: 15498145 Review.

3

Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.

Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Borghaei H, et al. J Immunother. 2007 May-Jun;30(4):455-67. doi: 10.1097/CJI.0b013e31803bb421. J Immunother. 2007. PMID: 17457220 Clinical Trial.

4

Immunotherapy of cancer.

Borghaei H, Smith MR, Campbell KS. Borghaei H, et al. Eur J Pharmacol. 2009 Dec 25;625(1-3):41-54. doi: 10.1016/j.ejphar.2009.09.067. Epub 2009 Oct 20. Eur J Pharmacol. 2009. PMID: 19837059 Free PMC article. Review.

5

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.

Stinchcombe TE, Borghaei H, Barker SS, Treat JA, Obasaju C. Stinchcombe TE, et al. Among authors: borghaei h. Clin Lung Cancer. 2016 Jan;17(1):1-9. doi: 10.1016/j.cllc.2015.07.002. Epub 2015 Jul 30. Clin Lung Cancer. 2016. PMID: 26340853 Review.

6

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.

Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. Goff LW, et al. Among authors: borghaei h. Clin Cancer Res. 2016 May 1;22(9):2146-54. doi: 10.1158/1078-0432.CCR-15-1622. Epub 2015 Dec 11. Clin Cancer Res. 2016. PMID: 26655846 Free PMC article. Clinical Trial.

7

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Arora S, et al. Among authors: borghaei h. Adv Ther. 2019 Oct;36(10):2638-2678. doi: 10.1007/s12325-019-01051-z. Epub 2019 Aug 13. Adv Ther. 2019. PMID: 31410780 Free PMC article. Review.

8

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Borghaei H, Schilder RJ. Borghaei H, et al. Semin Nucl Med. 2004 Jan;34(1 Suppl 1):4-9. doi: 10.1053/j.semnuclmed.2003.11.002. Semin Nucl Med. 2004. PMID: 14762738 Review.

9

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature.

Narra K, Borghaei H, Al-Saleem T, Höglund M, Smith MR. Narra K, et al. Among authors: borghaei h. Leuk Res. 2006 Jan;30(1):109-14. doi: 10.1016/j.leukres.2005.05.017. Epub 2005 Jul 25. Leuk Res. 2006. PMID: 16043218

10

Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Borghaei H, et al. J Thorac Oncol. 2008 Nov;3(11):1286-92. doi: 10.1097/JTO.0b013e318189f50e. J Thorac Oncol. 2008. PMID: 18978564 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters